Physician profile
Thinh D Mai
NPI 1558505750
$31,761.39
in general payments reported to CMS, 2019-2025
45 companies · $6,278 in 2025
The $6,278 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,702 · 2020: $2,091 · 2021: $4,334 · 2022: $4,899 · 2023: $5,110 · 2024: $6,347 · 2025: $6,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,599.86 |
| Education | $135.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,329.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $3,299.91 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $3,168.68 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,595.81 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,902.50 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,831.72 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,729.64 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $1,652.87 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $1,516.47 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $1,444.50 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $1,411.67 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,049.81 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $991.86 | 2019-2025 | Fanapt |
| Tris Pharma INC | $942.40 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Allergan, INC. | $737.53 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thinh Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.